Journal Francais D Ophtalmologie最新文献

{"title":"Fusarium keratitis on the rise in southern Europe: Implications of contact lens use and global warming","authors":"G. Pérez-García , N. Sabater Cruz , Z. del Campo Carrasco , V. Lázaro-Rodríguez , R. Delgado Weingartshofer , M.A. Gil Arnal , A. Montero García , M. Cobo de Nadal , I. Loscos Giménez","doi":"10.1016/j.jfo.2025.104576","DOIUrl":"10.1016/j.jfo.2025.104576","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the epidemiological and clinical characteristics of all cases of <em>Fusarium</em> spp. keratitis diagnosed in a southern European tertiary hospital over the last 20 years. To assess risk factors and prognostic determinants for <em>Fusarium</em> spp. keratitis.</div></div><div><h3>Methods</h3><div>In this case series, all cases of <em>Fusarium</em> spp. keratitis diagnosed at Hospital de la Santa Creu i Sant Pau, Barcelona, Spain between 2004 and 2023 were reviewed.</div></div><div><h3>Results</h3><div>Over 20 years, 7 cases of <em>Fusarium</em> spp. keratitis were detected. The initial ten-year period (2004–2013) accounted for one case, whereas six cases were diagnosed between 2013–2023. All patients related a history of contact lens use, and two had previous corneal diseases. All cultures were positive for <em>Fusarium solani</em>. Each case was treated with oral and topical voriconazole, three received topical natamycin and chlorhexidine, and five received intrastromal and intracameral medications. All cases required early penetrating keratoplasty. Three infection recurrences were reported, with two cases progressing to phthisis bulbi. In recurrent cases, antifungal treatment was started after 15 days, and therapeutic penetrating keratoplasty was delayed by 35.7 days. In cases without infection recurrence, the mean time to initiation of antifungal treatment was 9.7 days, and keratoplasty was performed after a mean delay of 26.7 days.</div></div><div><h3>Conclusions</h3><div>Fusarium keratitis is a serious ocular condition typically seen in tropical hot and humid areas. Its increase in temperate regions may be related to contact lens use and climate change. Prompt antifungal treatment, antifungal susceptibility testing, and early keratoplasty may be crucial for better outcomes.</div></div><div><h3>Objectifs</h3><div>Évaluer les caractéristiques épidémiologiques et cliniques des cas de kératite à <em>Fusarium</em> spp. diagnostiqués dans les hôpitaux de soins tertiaires du sud de l’Europe au cours des 20 dernières années. Déterminer les facteurs de risques et les facteurs pronostiques principaux de la kératite à <em>Fusarium</em> spp.</div></div><div><h3>Méthode</h3><div>Dans cette série de cas, nous avons analysé tous les cas de kératite à <em>Fusarium</em> spp. diagnostiqués au sein de l’hôpital de la Santa Creu i Sant Pau, Barcelone, Espagne, entre 2004 et 2023.</div></div><div><h3>Résultats</h3><div>Au cours des 20 dernières années, 7 cas de kératite à <em>Fusarium</em> spp. ont été détectés. Lors des 10 premières années (2004–2013), un cas a été enregistré, tandis que six cas ont été diagnostiqués entre 2013 et 2023. Tous les patients étaient des utilisateurs de lentilles de contact et deux patients avaient une pathologie cornéenne préexistante. Tous les cas ont été confirmés microbiologiquement par une culture positive à <em>Fusarium solani.</em> Le traitement consistait en l’administration de voric","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104576"},"PeriodicalIF":1.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of epithelial ingrowth following femtosecond laser LASIK flap lifts","authors":"M.R. Gemae ,&nbsp;D. Johnson","doi":"10.1016/j.jfo.2025.104572","DOIUrl":"10.1016/j.jfo.2025.104572","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the incidence of epithelial ingrowth (EI) following femtosecond LASIK (f-LASIK) flap relift.</div></div><div><h3>Methods</h3><div>This retrospective case series enrolled patients who underwent post-refractive enhancement surgery at a single independent outpatient health facility in Canada. Patients 18 years or older who underwent refractive enhancement surgery between July 2021 and December 2022 were eligible. We excluded patients with a history of cataract or refractive lens exchange surgery. Follow-ups were conducted at 1 week, 1 month, 3 months, 6 months, and 1 year postoperatively. The primary outcome was the incidence of EI following f-LASIK flap relifts. Secondary outcomes included other complications and visual outcomes 12 months postoperatively.</div></div><div><h3>Results</h3><div>Among the 103 included eyes, EI was reported in 41% of patients at some point in the follow-up period, with most EI present at one month and not requiring treatment. EI was three times less likely to develop if the enhancement was performed within one year of the original surgery (OR 0.31, <em>P</em> <!-->=<!--> <!-->0.023), and was 5–6 times more likely to develop if it was performed after three years (OR<!--> <!-->=<!--> <!-->0.17, <em>P</em> <!-->&lt;<!--> <!-->0.001). Successful treatment of EI by flap lift with sutures (<em>n</em> <!-->=<!--> <!-->2) and Nd:YAG laser (<em>n</em> <!-->=<!--> <!-->2) was performed in 4 eyes.</div></div><div><h3>Conclusions</h3><div>Only a small number (<em>n</em> <!-->=<!--> <!-->4) of EI post-flap lifts required treatment, and the procedure generally provided excellent long-term visual outcomes. Thus, f-LASIK flap lift is a safe option for refractive enhancement, even several years following the original surgery.</div></div><div><h3>Objectif</h3><div>Évaluer l’incidence de l’invasion épithéliale (IE) après un relèvement du volet LASIK au laser femtoseconde (f-LASIK).</div></div><div><h3>Méthodes</h3><div>Cette série de cas rétrospective a inclus des patients ayant subi une chirurgie de retouche réfractive dans un établissement de santé indépendant au Canada. Les patients âgés de 18 ans et plus ayant subi une retouche réfractive entre juillet 2021 et décembre 2022 étaient éligibles. Les patients ayant des antécédents de chirurgie de la cataracte ou d’échange de cristallin réfractif ont été exclus. Les suivis ont été effectués à 1 semaine, 1 mois, 3 mois, 6 mois et 1 an après l’opération. La mesure principale des résultats était l’incidence de l’IE après le relèvement du volet f-LASIK. Les critères secondaires incluaient d’autres complications et les résultats visuels à long terme (12 mois après l’opération).</div></div><div><h3>Résultats</h3><div>Parmi les 103 yeux inclus, une IE s’est développée chez 41 % des patients au cours de toute la période de suivi, la plupart des cas apparaissant à un mois et ne nécessitant pas de traitement. L’IE était trois fois moins susceptible de se dévelop","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104572"},"PeriodicalIF":1.2,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144472004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease control, visual and anatomic outcomes at week 48 of brolucizumab treatment in patients with previously suboptimal anatomically controlled neovascular age-related macular degeneration – The SWIFT study","authors":"A. Couturier ,&nbsp;E.H. Souied ,&nbsp;C. Creuzot-Garcher ,&nbsp;S.Y. Cohen ,&nbsp;L. Kodjikian ,&nbsp;S. Baillif ,&nbsp;M.-N. Delyfer ,&nbsp;M. Weber ,&nbsp;I. Aubry-Quenet ,&nbsp;A. Ponthieux ,&nbsp;F. Devin","doi":"10.1016/j.jfo.2025.104574","DOIUrl":"10.1016/j.jfo.2025.104574","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Neovascular age-related macular degeneration (nAMD) patients refractory to one anti-vascular endothelial growth factor (VEGF) agent often switch to another anti-VEGF for better disease control. Our objective is to assess nAMD control with brolucizumab 6&lt;!--&gt; &lt;!--&gt;mg treatment in previously treated patients with suboptimal anatomical control.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;SWIFT was a 48-week, prospective, single-arm, open-label clinical trial at 52 sites in France (&lt;span&gt;&lt;span&gt;NCT04264819&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;). Participants were adults (≥ 50 years) with active CNV lesions secondary to nAMD, diagnosed&lt;!--&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;18 months, previously treated with either ranibizumab or aflibercept with a 4- or 8-week interval treatment, with baseline BCVA 38–83 letters. Eyes were treated with intravitreal brolucizumab 6&lt;!--&gt; &lt;!--&gt;mg at weeks 0, 4 and 8 (loading phase), followed by treat-to-control dosing with intervals up to 16 weeks, depending on investigator-assessed disease activity. The main outcome is the proportion of eyes without investigator-assessed disease activity at week 16.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Two hundred and eighty-nine patients were included and analyzed (mean age 76.3 years, 61.9% female). Eyes were previously treated for a mean of 9.1 months. Baseline mean BCVA was 68.9 letters, and central subfield foveal thickness (CSFT) was 417&lt;!--&gt; &lt;!--&gt;μm. Over the course of the study, patients received a median of 6 brolucizumab injections (range: 1–8) with a mean (SD) treatment duration of 32.1 (14.1) weeks. The mean last brolucizumab treatment interval (SD) was 8.7 (3.5) weeks, notably longer than the interval of 6.2 (2.8) weeks with the previous anti-VEGF agent before inclusion in SWIFT. The proportion of eyes with no disease activity was 41.0% (95% CI: 34.4–47.9) at week 16 and 52.0% at week 48 (47.0 and 43.4%, respectively, using last observation carried forward sensitivity analysis). Improvements were observed from baseline to week 48 in BCVA (mean +3.2 [9.2] letters; &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.0001), CFST (–66 [101] μm; &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.0001). At week 48, 22% of eyes were on a regimen of every 12 weeks or more, and 40.4% of eyes had no retinal fluid (36.0 and 42.4% had intraretinal and subretinal fluid respectively). Intraocular inflammation (IOI) was confirmed in 29/295 (9.8%) eyes. Four of these patients had BCVA losses of&lt;!--&gt; &lt;!--&gt;≥&lt;!--&gt; &lt;!--&gt;15 letters at or after IOI resolution.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In patients with refractory nAMD, brolucizumab allowed control of disease activity for up to 41.0% of patients, with visuals gains, anatomical improvements and extended treatment interval, despite poor response and discontinuation for some patients in addition to a 9.8% rate of IOI.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;div&gt;Les patients atteints de dégénérescence maculaire néovasculaire liée à l’âge (DMLA néovasculaire) réfractaire à ","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104574"},"PeriodicalIF":1.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conjunctival burn using micropulse transscleral cyclophotocoagulation","authors":"V. Vermot-Desroches,&nbsp;A. Barbarroux,&nbsp;L. Sejournet,&nbsp;P. Denis","doi":"10.1016/j.jfo.2025.104568","DOIUrl":"10.1016/j.jfo.2025.104568","url":null,"abstract":"<div><div>We report the case of a 37-year-old patient who experienced a conjunctival burn due to overheating of the probe of a micropulse transscleral cyclophotocoagulation device. Fortunately, the outcome was favorable; however, the persistent conjunctival fibrosis may pose future surgical problems for this young glaucoma patient. It is essential to be aware of this rare complication and to take appropriate precautions to prevent it.</div></div><div><div>Nous rapportons le cas d’un patient de 37 ans, qui a présenté une brûlure conjonctivale due à une surchauffe de la sonde du laser diode micropulsé lors d’un cyclo-affaiblissement. Heureusement, l’évolution fut favorable ; mais la fibrose sous conjonctivale persistante pourrait entraîner de futures complications chirurgicales pour ce jeune patient atteint de glaucome. Il est important de connaître cette complication rare, et de prendre les précautions appropriées pour la prévenir.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104568"},"PeriodicalIF":1.2,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change in intraocular lens power calculation results after ptosis surgery","authors":"M. Mutlu Sönmez ,&nbsp;E. Savran Elibol ,&nbsp;H. Oğuz","doi":"10.1016/j.jfo.2025.104571","DOIUrl":"10.1016/j.jfo.2025.104571","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the difference between intraocular lens power calculation and ocular biometric parameters before and after anterior levator resection surgery (ALR).</div></div><div><h3>Methods</h3><div>In this prospective study, patients with involutional ptosis who underwent ALR surgery were included. Ocular biometric parameters were obtained preoperatively and 3 and 6 months postoperatively.</div></div><div><h3>Results</h3><div>Forty-five patients with ptosis were selected for the study, 25 eyes had only ALR surgery, and 20 eyes had both ALR and upper lid blepharoplasty. The mean keratometry (Km) value significantly decreased from the preoperative value at 3 months postoperatively (<em>P</em> <!-->=<!--> <!-->0.026) and did not change between 3 and 6 months (<em>P</em> <!-->=<!--> <!-->0.4). The mean preoperative MRD-1 level was 0.86<!--> <!-->±<!--> <!-->1.1<!--> <!-->mm, 3.4<!--> <!-->±<!--> <!-->0.9<!--> <!-->mm at 3 months, and 3.45<!--> <!-->±<!--> <!-->1<!--> <!-->mm at 6 months postoperatively (<em>P</em> <!-->=<!--> <!-->0.0001). The mean IOL power targeting emmetropia increased at 3 months postoperatively (<em>P</em> <!-->=<!--> <!-->0.041) and did not change between 3 and 6 months (<em>P</em> <!-->=<!--> <!-->0.2). There was a negative correlation between MRD-1 level, K1, K2 and Km after 6 months (<em>r</em>: –0.171, <em>P</em>: 0.02; <em>r</em>: –0.334, <em>P</em>: 0.04; <em>r</em>: –041, <em>P</em>: 0.001 respectively), whereas there was a positive correlation between MRD-1 level and IOL power after 6 months (<em>r</em>: 0.348, <em>P</em>: 0.04). The mean Km, IOL power and MRD-1 levels were not statistically different between ALR-only patients and ALR-blepharoplasty patients at 6 months postoperatively (<em>P</em>: 0.2, 0.07, 0.32 respectively).</div></div><div><h3>Conclusion</h3><div>Ptosis surgery can affect IOL power postoperatively due to keratometric changes, and these changes stabilize at 3 months after surgery. Keratometric measurements have been shown to be related to postoperative eyelid position.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104571"},"PeriodicalIF":1.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chatbots in keratorefractive surgery patient education","authors":"H. Daungsupawong ,&nbsp;V. Wiwanitkit","doi":"10.1016/j.jfo.2025.104569","DOIUrl":"10.1016/j.jfo.2025.104569","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104569"},"PeriodicalIF":1.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0181-5512(25)00146-9","DOIUrl":"10.1016/S0181-5512(25)00146-9","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 6","pages":"Article 104564"},"PeriodicalIF":1.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144170393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice of: Retroprosthetic Membrane Formation in Boston Keratoprosthesis Type 1: Incidence, Predisposing Factors, Complications, and Treatment [J. Fr. Ophtalmol. 47 (2024) 103995]","authors":"M. Mina ,&nbsp;M. Harissi-Dagher","doi":"10.1016/j.jfo.2025.104547","DOIUrl":"10.1016/j.jfo.2025.104547","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 6","pages":"Article 104547"},"PeriodicalIF":1.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tomographie par cohérence optique-angiographie (Optical coherence tomography angiography (OCTA) et nerf optique (hors glaucome)","authors":"H. Merle ,&nbsp;M. Pierre ,&nbsp;A. Jean-Charles","doi":"10.1016/j.jfo.2025.104546","DOIUrl":"10.1016/j.jfo.2025.104546","url":null,"abstract":"<div><div>La tomographie par cohérence optique-angiographie (<em>optical coherence tomography angiography</em> ([OCTA]) est un examen non invasif, fiable et reproductible. Contrairement à l’angiographie à la fluorescéine, l’OCTA permet d’analyser le lit capillaire sans être gêné par les phénomènes de diffusion. Son emploi est maintenant largement répandu pour le diagnostic et le suivi des maladies rétiniennes et choroïdiennes. Cependant, son usage dans l’exploration du nerf optique est encore limité. Récemment, l’arrivée de logiciels qui permettent une quantification des données, complètent les images de la vascularisation maculaire et papillaire. Cette revue expose les résultats obtenus en OCTA au cours de l’exploration des principales affections du nerf optique acquises ou congénitales en dehors de la neuropathie optique glaucomateuse. Dans la plupart des cas, l’OCTA montrent des modifications de la vascularisation rétinienne ou papillaire en corrélation avec l’atteinte des fibres nerveuses rétiniennes, de la couche des cellules ganglionnaires et la fonction visuelle. L’OCTA contribue à améliorer la compréhension physiopathologique des affections du nerf optique sans pouvoir encore préciser si ces modifications sont une cause ou une conséquence de la maladie. L’utilisation de l’OCTA est pertinente en neuro-ophtalmologie. Outre la détection et le diagnostic, l’OCTA pourrait être employé pour le suivi ou la surveillance des traitements mis en place.</div></div><div><div>Optical coherence tomography angiography (OCTA) is a non-invasive, reliable, repeatable exam. As opposed to fluorescein angiography, OCTA allows analysis of the capillary bed without interference from diffusion phenomena. It is now widely used for both the diagnosis and ongoing care of retinal and choroidal diseases. However, its use is still limited for evaluation of the optic nerve. Recently, new data quantification software can add value to macular and papillary vascularization images. This review details OCTA results in the most important optic nerve conditions, whether acquired or congenital, other than glaucoma. In most cases, OCTA shows modifications of the retinal or papillary vascularization systematically impacting retinal nerve fibers, ganglion cells layer and visual acuity. OCTA contributes to a better understanding of the pathophysiology of optic nerve disease without being able to specify yet whether the modifications cause or are caused by the disease. OCTA is particularly useful for neuro-ophthalmology. In addition to detection and diagnosis, OCTA can be used for follow-up and monitoring of treatment response.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 6","pages":"Article 104546"},"PeriodicalIF":1.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study","authors":"L. Béal ,&nbsp;M. Lamiaux ,&nbsp;E. Guerrien-Sevrin ,&nbsp;A. Lasek ,&nbsp;P. Modiano ,&nbsp;S. Doan ,&nbsp;T.H.C. Tran","doi":"10.1016/j.jfo.2025.104544","DOIUrl":"10.1016/j.jfo.2025.104544","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To describe the ocular surface findings in atopic dermatitis patients treated with dupilumab.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;This is an observational study including atopic dermatitis patients treated with dupilumab from January 2018 to July 2019. At baseline, patients underwent dermatological and ophthalmological assessments and at least one other joint visit during the 6-month follow-up. Appointments were scheduled at baseline, 1, 3, and 6&lt;!--&gt; &lt;!--&gt;months for ophthalmologists. Ocular assessment included past ocular history and symptoms, Ocular Surface Disease Index (OSDI) score, slit lamp examination, tear film Break Up Time and Schirmer's test. Atopic dermatitis severity scores were assessed at baseline and 3 and 6&lt;!--&gt; &lt;!--&gt;months by dermatologists.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Forty-six patients were included. Among them, 31 (67%) had preexisting ocular surface disease at baseline. Mean follow-up was 7.1&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;1.6&lt;!--&gt; &lt;!--&gt;months. At the 6-month endpoint, 8 patients (17%) developed newly diagnosed ocular surface disease; 13 patients (28%) experienced exacerbation of ocular surface disease; 8 patients (17%) had stable ocular surface disease, 10 patients (22%) experienced an improvement in their ocular surface disease on dupilumab, and 7 patients (15%) had no ocular surface disease from baseline to the endpoint. The presence of eyelid eczema at baseline was associated with the occurrence of dupilumab induced ocular surface disease. Only 3 patients (7%) had to discontinue treatment due to ocular adverse events.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Atopic dermatitis patients treated with dupilumab may develop polymorphic, potentially severe ocular surface disease. These results highlight the need for careful examination of the eyelids and globe of atopic dermatitis patients and early examination by ophthalmologists if conjunctivitis does not resolve with non-steroid eye drops.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Décrire les atteintes de surface oculaire au cours des dermatites atopiques sous dupilumab.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthode&lt;/h3&gt;&lt;div&gt;Il s’agit d’une étude observationnelle réalisée entre janvier 2018 et juillet 2019, chez des patients ayant une dermatite atopique et pour qui du dupilumab a été introduit. Le suivi ophtalmologique a été réalisé à l’inclusion, au 1&lt;sup&gt;er&lt;/sup&gt;, 3&lt;sup&gt;e&lt;/sup&gt; et 6&lt;sup&gt;e&lt;/sup&gt; mois. L’ophtalmologue évaluait les antécédents et les symptômes oculaires, le score OSDI (Ocular Surface Disease Index), le segment antérieur en biomicroscopie, le BUT et réalisait un test de Schirmer. L’examen dermatologique déterminait le score de sévérité de la dermatite atopique à l’inclusion, au 3&lt;sup&gt;e&lt;/sup&gt; et au 6&lt;sup&gt;e&lt;/sup&gt; mois.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Quarante-six patients ont été inclus. Trente et un (67 %) avaient dès l’inclusion une atteinte pré-existante de surface oculaire. Le suivi moyen était de 7,1&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;1,6 mois. À 6 mois, 8 pa","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 6","pages":"Article 104544"},"PeriodicalIF":1.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}